BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $111 at Barclays
August 17, 2026 4:51 AM
Barclays analyst Eliana Merle raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $111.00 (from $105.00) while maintaining a Overweight rating.
